mTOR signaling in epilepsy: Insights from malformations of cortical development

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 4, 2015, Pages

  Crino, Peter B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ALEXANDER DISEASE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BRAIN MALFORMATION; CELL DIVISION; CELL GROWTH; CELL SIZE; CELL SURVIVAL; CORTICAL DYSPLASIA; DISEASE CLASSIFICATION; EPILEPSY; EPILEPTOGENESIS; HUMAN; NERVE EXCITABILITY; NEUROPATHOLOGY; PRETZEL SYNDROME; SIGNAL TRANSDUCTION; ANIMAL; CLASSIFICATION; DISEASE MODEL; GENETICS; MOUSE; MUTATION; PATHOLOGY; TUBEROUS SCLEROSIS;

MAMMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; MALFORMATIONS OF CORTICAL DEVELOPMENT; MICE; MUTATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84926372078     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a022442     Document Type: Article

References (134)

1. Abs E, Goorden SM, Schreiber J, Overwater IE, HoogeveenWesterveld M, Bruinsma CF, Aganović E, Borgesius NZ, Nellist M, Elgersma Y. 2013. TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice. Ann Neurol 74: 569-579.
2. Anderl S, Freeland M, Kwiatkowski DJ, Goto J. 2011. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet 20: 4597-4604.
3. Aronica E, Crino PB. 2014. Epilepsy related to developmental tumors and malformations of cortical development. Neurotherapeutics 11: 251-268.
4. Aronica E, Boer K, Baybis M, Yu J, Crino P. 2007. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol 114: 287-293.
5. Aronica E, Becker AJ, Spreafico R. 2012. Malformations of cortical development. Brain Pathol 22: 380-401.
6. Barkovich AJ, Kuzniecky RI, Dobyns WB, Jackson GD, Becker LE, Evrard P. 1996. A classification scheme for malformations of cortical development. Neuropediatrics 1996: 9-63.
7. Barkovich AJ, Guerrini R, Kuzniecky RI, Jackson GD, Dobyns WB. 2012. A developmental and genetic classification for malformations of cortical development: Update 2012. Brain 135: 1348-1369.
8. Bateup HS, Johnson CA, Denefrio CL, Saulnier JL, Kornacker K, Sabatini BL. 2013. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 78: 510- 522.
9. Baulac S, Ishida S, Marsan E, Miquel C, Biraben A, Nguyen DK, Nordli D, Cossette P, Nguyen S, Lambrecq V, et al. 2015. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol doi: 10.1002/ ana.24368.
10. Baybis M, Yu J, Lee A, Golden JA, Weiner H, McKhann G II, Aronica E, Crino P.. 2004. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol 56: 478-487.
11. Baybis M, Aronica E, Nathanson KL, Crino PB. 2009. Deletion of 15q11.2-15q13.1 in isolated human hemimegalencephaly. Acta Neuropathol 118: 821-823.
12. Becker LE. 1995. Central neuronal tumors in childhood: Relationship to dysplasia. J Neurooncol 24: 13-19.
13. Becker AJ, Urbach H, Scheffler B, Baden T, Normann S, Lahl R, Pannek HW, Tuxhorn I, Elger CE, Schramm J, et al. 2002. Focal cortical dysplasia of Taylor’s balloon cell type: Mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann Neurol 52: 29-37.
14. Becker AJ, Blumcke I, Urbach H, Hans V, Majores M. 2006. Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol 65: 99-108.
15. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. 2013. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339: 1323- 1328.
16. Berdichevsky Y 1, Dryer AM, Saponjian Y, Mahoney MM, Pimentel CA, Lucini CA, Usenovic M, Staley KJ. 2013. PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. J Neurosci 33: 9056-9067.
17. Blumcke I, Muhlebner A. 2011. Neuropathological work-up of focal cortical dysplasias using the new ILAE consensus classification system—Practical guideline article invited by the Euro-CNS Research Committee. Clin Neuropathol 30: 164-177.
18. Blumcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, Pietsch T, Wolf HK, Schramm J, Elger CE, et al. 1999. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 97: 481-490.
19. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, Jacques TS, Avanzini G, Barkovich AJ, Battaglia G, et al. 2011. The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52: 158-174.
20. Boer K, Troost D, Spliet WG, Redeker S, Crino P., Aronica E. 2007. A neuropathological study of two autopsy cases of syndromic hemimegalencephaly. Neuropathol Appl Neurobiol 33: 455-470.
21. Boer K, Troost D, Jansen F, Nellist M, van den Ouweland AM, Geurts JJ, Spliet WG, Crino P, Aronica E. 2008a. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. Neuropathology 28: 577-590.
22. Boer K, Troost D, Spliet WG, van Rijen PC, Gorter JA, Aronica E. 2008b. Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB. Acta Neuropathol 115: 683-696.
23. Boer K, Troost D, Timmermans W, van Rijen PC, Spliet WG, Aronica E. 2010. PI3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 20: 234-244.
24. Bosnjak VM, Dakovic I, Duranovic V, Lujic L, Krakar G, Marn B. 2011. Malformations of cortical development in children with congenital cytomegalovirus infection—A study of nine children with proven congenital cytomegalovirus infection. Coll Antropol 35: 229-234.
25. Bourneville D. 1880. Sclérose tubéreuse des circonvolutions cérébrales: Idiotie et épilepsie hémiplégique. Arch Neurol (Paris) 1: 81-91.
26. Brewster AL 1, Lugo JN, Patil VV, Lee WL, Qian Y, Vanegas F, Anderson AE. 2013. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage. PLoS ONE 8: e57808.
27. Buckmaster PS, Lew FH. 2011. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 31: 2337-2347.
28. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, et al. 2005. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42: 318-321.
29. Calcagnotto ME 1, Paredes MF, Tihan T, Barbaro NM, Baraban SC. 2005. Dysfunction of synaptic inhibition in epilepsy associated with focal cortical dysplasia. J Neurosci 25: 9649-9657.
30. Capo-Chichi JM, Tcherkezian J, Hamdan FF, Décarie JC, Dobrzeniecka S, Patry L, Nadon MA, Mucha BE, Major P, Shevell M, et al. 2013. Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. J Med Genet 50: 740-744.
31. Chen J, Tsai V, Parker WE, Aronica E, Baybis M, Crino PB. 2012a. Detection of human papillomavirus in human focal cortical dysplasia type IIB. Ann Neurol 72: 881-892.
32. Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu H. 2012b. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS ONE 7: e42598.
33. Cho CH. 2011. Frontier of epilepsy research—mTOR signaling pathway. Exp Mol Med 43: 231-274.
34. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. 2010. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51: 1236-1241.
35. Colombo N, Salamon N, Raybaud C, Ozkara C, Barkovich AJ. 2009. Imaging of malformations of cortical development. Epileptic Disord 11: 194-205.
36. Crino PB. 2005. Molecular pathogenesis of focal cortical dysplasia and hemimegalencephaly. J Child Neurol 20: 330-336.
37. Crino PB. 2007. Focal brain malformations: A spectrum of disorders along the mTOR cascade. Novartis Foundation Symposium 288: 260-272; discussion 272-281.
38. Crino PB. 2009. Focal brain malformations: Seizures, signaling, sequencing. Epilepsia 50: 3-8.
39. Crino P.. 2011. mTOR: A pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 17: 734-742.
40. Crino PB. 2013. Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol 125: 317-332.
41. Crino P., Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N Engl J Med 355: 1345-1356.
42. Crino P., Aronica E, Baltuch G, Nathanson KL. 2010. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74: 1716-1723.
43. Dibbens LM, de Vries B, Donatello S, Heron SE, Hodgson BL, Chintawar S, Crompton DE, Hughes JN, Bellows ST, Klein KM, et al. 2013. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 45: 546-551.
44. Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD. 2012. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 47: 535-546.
45. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. 2011. Mammalian target of rapamycin: A central node of complex signaling cascades. Int J Clin Exp Pathol 4: 476-495.
46. Epi4K Consortium; Epilepsy Phenome/Genome Project,Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, et al. 2013. De novo mutations in epileptic encephalopathies. Nature 501: 217-221.
47. Faustino A, Couto JP, Pópulo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simões M, Soares P. 2012. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 97: E1139-E1149.
48. Feliciano DM, Su T, Lopez J, Platel JC, Bordey A. 2011. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest 121: 1596-1607.
49. Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, Lafourcade C, O’Keefe RA, Bordey A. 2013. A circuitry and biochemical basis for tuberous sclerosis symptoms: From epilepsy to neurocognitive deficits. Int J Dev Neurosci 31: 667-678.
50. Flores-Sarnat L, Sarnat HB, Davila-Gutierrez G, Alvarez A. 2003. Hemimegalencephaly: Part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol 18: 776-785.
51. Galanopoulou AS, Gorter JA, Cepeda C. 2012. Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic target. Epilepsia 53: 1119-1130.
52. Guerrini R, Dobyns WB. 2014. Malformations of cortical development: Clinical features and genetic causes. Lancet Neurol 13: 710-726.
53. Gumbinger C, Rohsbach CB, Schulze-Bonhage A, Korinthenberg R, Zentner J, Haffner M, Fauser S. 2009. Focal cortical dysplasia: A genotype-phenotype analysis of polymorphisms and mutations in the TSC genes. Epilepsia 50: 1396-1408.
54. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, et al. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332: 1317-1322.
55. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
56. Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D. 2013. Mutant BRAF V600E protein in gan glioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 6: 891-900.
57. Krsek P, Maton B, Korman B, Pacheco-Jacome E, Jayakar P, Dunoyer C, Rey G, Morrison G, Ragheb J, Vinters HV, et al. 2008. Different features of histopathological subtypes of pediatric focal cortical dysplasia. Ann Neurol 63: 758- 769.
58. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. 2010. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801- 1811.
59. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN. 2013. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74: 679-687.
60. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of pp70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11: 525-534.
61. Kwon CH, Zhu X, Zhang J, Baker SJ. 2003. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci 100: 12923-12928.
62. Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF. 2006. Pten regulates neuronal arborization and social interaction in mice. Neuron 50: 377-388.
63. Lal D, Reinthaler EM, Schubert J, Muhle H, Riesch E, Kluger G, Jabbari K, Kawalia A, Bäumel C, Holthausen H, et al. 2014. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol 75: 788-792.
64. Lamparello P, Baybis M, Pollard J, Hol EM, Eisenstat DD, Aronica E, Crino PB. 2007. Developmental lineage of cell types in cortical dysplasia with balloon cells. Brain 130: 2267-2276.
65. Lasarge CL, Danzer SC. 2014. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front Mol Neurosci 7: 18.
66. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, et al. 2012. De novo somatic mutations in components of the PI3KAKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 44: 941-945.
67. Liu S, Lu L, Cheng X, Xu G, Yang H. 2014. Viral infection and focal cortical dysplasia. Ann Neurol 75: 614-616.
68. Ljungberg MC, Bhattacharjee MB, Lu Y, Armstrong DL, Yoshor D, Swann JW, Sheldon M, D’Arcangelo G. 2006. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol 60: 420-429.
69. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468.
70. Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, et al. 2010. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 120: 103-114.
71. Manoranjan B, Provias JP. 2010. Hemimegalencephaly: A fetal case with neuropathological confirmation and review of the literature. Acta Neuropathol 120: 117-130.
72. Marucci G, Martinoni M, Giulioni M. 2013. Relationship between focal cortical dysplasia and epilepsy-associated low-grade tumors: An immunohistochemical study. APMIS 121: 22-29.
73. Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. 2007. A mouse model of tuberous sclerosis: Neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 27: 5546-5558.
74. Menon S, Manning BD. 2008. Common corruption of the mTOR signaling network in human tumors. Oncogene 27: S43-S51.
75. Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD. 2014. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156: 771-785.
76. Mirzaa GM, Dobyns WB. 2013. The “megalencephaly-capillary malformation” (MCAP) syndrome: The nomenclature of a highly recognizable multiple congenital anomaly syndrome. Am J Med Genet A 161A: 2115-2116.
77. Mischel PS, Nguyen LP, Vinters HV. 1995. Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. J Neuropathol Exp Neurol 54: 137-153.
78. Miyata H, Chiang AC, Vinters HV. 2004. Insulin signaling pathways in cortical dysplasia and TSC-tubers: Tissue microarray analysis. Ann Neurol 56: 510-519.
79. Muhlebner A, Coras R, Kobow K, Feucht M, Czech T, Stefan H, Weigel D, Buchfelder M, Holthausen H, Pieper T, et al. 2012. Neuropathologic measurements in focal cortical dysplasias: Validation of the ILAE 2011 classification system and diagnostic implications for MRI. Acta Neuropathol 123: 259-272.
80. Orlova KA, Crino PB. 2010. The tuberous sclerosis complex. Ann NY Acad Sci 1184: 87-105.
81. Orlova KA, Parker WE, Heuer GG, Tsai V, Yoon J, Baybis M, Fenning RS, Strauss K, Crino PB. 2010a. STRADa deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest 120: 1591- 1602.
82. Orlova KA, Tsai V, Baybis M, Heuer GG, Sisodiya S, Thom M, Strauss K, Aronica E, Storm PB, Crino PB. 2010b. Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropathol Exp Neurol 69: 850-863.
83. Palmini A, Najm I, Avanzini G, Babb T, Guerrini R, Foldvary-Schaefer N, Jackson G, Luders HO, Prayson R, Spreafico R, et al. 2004. Terminology and classification of the cortical dysplasias. Neurology 62: S2-S8.
84. Parker WE, Orlova KA, Heuer GG, Baybis M, Aronica E, Frost M, Wong M, Crino PB. 2011. Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Am J Pathol 178: 296-305.
85. Parker WE, Orlova KA, Parker WH, Birnbaum JF, Krymskaya VP, Goncharov DA, Baybis M, Helfferich J, Okochi K, Strauss KA, et al. 2013. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 5: 182ra53.
86. Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, et al. 2012. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74: 41-48.
87. Prabowo AS, Anink JJ, Lammens M, Nellist M, van den Ouweland AM, Adle-Biassette H, Sarnat HB, Flores-Sarnat L, Crino P., Aronica E. 2013. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol 23: 45-59.
88. Puffenberger EG, Strauss KA, Ramsey KE, Craig DW, Stephan DA, Robinson DL, Hendrickson CL, Gottlieb S, Ramsay DA, Siu VM, et al. 2007. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain 130: 1929- 1941.
89. Pun RY, Rolle IJ, Lasarge CL, Hosford BE, Rosen JM, Uhl JD, Schmeltzer SN, Faulkner C, Bronson SL, Murphy BL, et al. 2012. Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy. Neuron 75: 1022-1034.
90. Qin W, Chan JA, Vinters HV, Mathern GW, Franz DN, Taillon BE, Bouffard P, Kwiatkowski DJ. 2010. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol 20: 1096- 1105.
91. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS. 2011. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 43: 322-329.
92. Reith RM, Way S, McKenna J III, Haines K, Gambello MJ. 2011. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis 43: 113-122.
93. Reith RM, McKenna J, Wu H, Hashmi SS, Cho SH, Dash PK, Gambello MJ. 2013. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol Dis 51: 93-103.
94. Riviere JB, Mirzaa GM, O’Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, et al. 2012. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44: 934-940.
95. Russell RC, Fang C, Guan KL. 2011. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 138: 3343-3356.
96. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. 1995. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270: 815-822.
97. Samadani U, Judkins AR, Akpalu A, Aronica E, Crino PB. 2007. Differential cellular gene expression in ganglioglioma. Epilepsia 48: 646-653.
98. Sha LZ, Xing XL, Zhang D, Yao Y, Dou WC, Jin LR, Wu LW, Xu Q. 2012. Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy. PLoS ONE 7: e39152.
99. Scheffer IE, Heron SE, Regan BM, Mandelstam S, Crompton DE, Hodgson BL, Licchetta L, Provini F, Bisulli F, Vadlamudi L, et al. 2014. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 75: 782-787.
100. Schick V, Majores M, Engels G, Hartmann W, Elger CE, Schramm J, Schoch S, Becker AJ. 2007a. Differential PI3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells. Brain Pathol 17: 165- 173.
101. Schick V, Majores M, Koch A, Elger CE, Schramm J, Urbach H, Becker AJ. 2007b. Alterations of phosphatidylinositol 3-kinase pathway components in epilepsy-associated glioneuronal lesions. Epilepsia 48: 65-73.
102. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, et al. 2011. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121: 397-405.
103. Sims J. 1835. On hypertrophy and atrophy of the brain. Med Chir Trans 19: 315-380.
104. Sisodiya SM. 2004. Malformations of cortical development: Burdens and insights from important causes of human epilepsy. Lancet Neurol 3: 29-38.
105. Sliwa A, Plucinska G, Bednarczyk J, Lukasiuk K. 2012. Posttreatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett 509: 105-109.
106. Sosunov AA, Wu X, McGovern RA, Coughlin DG, Mikell CB, Goodman RR, McKhann GM II. 2012. The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia 53: 78-86.
107. Southwell DG, Garcia PA, Berger MS, Barbaro NM, Chang EF. 2012. Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 70: 1406-1413.
108. Talos DM, Kwiatkowski DJ, Cordero K, Black PM, Jensen FE. 2008. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 63: 454-465.
109. Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, Klein PM, Lan VJ, Joseph A, Jensen FE. 2012. The interaction between early life epilepsy and autistic-like behavioral consequences: A role for the mammalian target of rapamycin (mTOR) pathway. PloS ONE 7: e35885.
110. Tassi L, Colombo N, Garbelli R, Francione S, Lo Russo G, Mai R, Cardinale F, Cossu M, Ferrario A, Galli C, et al. 2002. Focal cortical dysplasia: Neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain 125: 1719-1732.
111. Taylor DC, Falconer MA, Bruton CJ, Corsellis JA. 1971. Focal dysplasia of the cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry 34: 369-387.
112. Theilhaber J 1, Rakhade SN, Sudhalter J, Kothari N, Klein P, Pollard J, Jensen FE. 2013. Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis. PLoS ONE 8: e74428.
113. Tinkle BT, EK Schorry, DN Franz, KR Crone, HM Saal. 2005. Epidemiology of hemimegalencephaly: A case series and review. Am J Med Genet A 139: 204-211.
114. Tsai PT, Hull C, Chu Y, Greene-Colozzi E, Sadowski AR, Leech JM, Steinberg J, Crawley JN, Regehr WG, Sahin M. 2012a. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 488: 647- 651.
115. Tsai V, Parker WE, Orlova KA, Baybis M, Chi AW, Berg BD, Birnbaum JF, Estevez J, Okochi K, Sarnat HB, et al. 2012b. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex 24: 315-327.
116. Tsai PT, Greene-Colozzi E, Goto J, Anderl S, Kwiatkowski DJ, Sahin M. 2013. Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 mice. Behav Genet 43: 51-59.
117. Urbanska M, Gozdz A, Swiech LJ, Jaworski J. 2012. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J Biol Chem 287: 30240-30256.
118. Van Vliet EA, Forte G, Holtman L, den Burger JC, Sinjewel A, de Vries HE, Aronica E, Gorter JA. 2012. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia 53: 1254-1263.
119. Vaughn J, Hagiwara M, Katz J, Roth J, Devinsky O, Weiner H, Milla S. 2013. MRI characterization and longitudinal study of focal cerebellar lesions in a young tuberous sclerosis cohort. AJNR Am J Neuroradiol 34: 655-659.
120. Way SW, McKenna J III, Mietzsch U, Reith RM, Wu HC, Gambello MJ. 2009. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 18: 1252-1265.
121. Way SW, Rozas NS, Wu HC, McKenna J III, Reith RM, Hashmi SS, Dash PK, Gambello MJ. 2012. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum Mol Genet 21: 3226-3236.
122. Weber JD, Gutmann DH. 2012. Deconvoluting mTOR biology. Cell Cycle 11: 236-248.
123. Weston MC, Chen H, Swann JW. 2014. Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures. Front Mol Neurosci 7: 1.
124. White R, Hua Y, Scheithauer B, Lynch DR, Henske EP, Crino PB. 2001. Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann Neurol 49: 67-78.
125. Wong M. 2008. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia 49: 8-21.
126. Wong M. 2013. A critical review of mTOR inhibitors and epilepsy: From basic science to clinical trials. Expert Rev Neurother 13: 657-669.
127. Wong M, Crino P. 2012. mTOR and epileptogenesis in developmental brain malformations. In: Jasper’s basic mechanisms of the epilepsies (ed. Noebels JL, et al.). National Center for Biotechnology Information, Bethesda, MD.
128. Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, Nicholson SL, Harkness W, Cross JH, Paine SM, et al. 2013. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: Evidence from focal cortical dysplasia and tuberous sclerosis. Acta Neuropathol 126: 207-218.
129. Zeng LH, Xu L, Gutmann DH, Wong M. 2008. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63: 444-453.
130. Zeng LH, Rensing NR, Wong M. 2009. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29: 6964-6972.
131. Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. 2011. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 20: 445-454.
132. Zhou H, Huang S. 2011. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci 12: 30-42.
133. Zhou Y, Pan Y, Zhang S, Shi X, Ning T, Ke Y. 2007. Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer. Br J Cancer 97: 218-222.
134. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.